ARS Pharma rises after Q2 revenue beats estimates

** Shares of drug developer ARS Pharmaceuticals SPRY.O rise 3.7% to $17.28 premarket

** Company reports Q2 revenue of $15.72 million, beating estimates of $13.78 million

** Company expects regulatory approval for its nasal spray, neffy, in Canada, Japan and Australia by end of 2025, with commercial rollouts planned in H1 2026

** "As the volume of neffy continues to increase, we anticipate that the economic factors for the remaining PBMs will continue to reduce prior authorization requirements," says Chief Commercial Officer Eric Karas

** Expects regulatory approval for neffy in China in H1 2026

** ARS Pharma had cash, cash equivalents, and short-term investments of $240.1 million as of June 30

** Up to last close, stock up 57.9% YTD